feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Diabetes Drug May Halt Vision Loss

Diabetes Drug May Halt Vision Loss

11 Feb

•

Summary

  • Metformin use linked to 37% lower risk of intermediate AMD.
  • Study involved 2,000 diabetic patients over five years.
  • Researchers see potential for metformin in AMD treatment.
Diabetes Drug May Halt Vision Loss

A common medication for type 2 diabetes, metformin, shows potential in slowing age-related vision loss. New research from the University of Liverpool suggests that individuals over 55 with diabetes who take metformin are 37% less likely to develop intermediate age-related macular degeneration (AMD). The study analyzed eye images from 2,000 diabetic patients over five years.

Researchers are optimistic about these findings, noting the lack of effective treatments for most AMD patients. They plan to conduct clinical trials to test metformin directly as an AMD treatment. However, they caution that this observational study only shows a link, not a direct cause.

Further investigation is needed to determine if metformin benefits individuals without diabetes. Additionally, the study did not track specific dosages or patient adherence to prescriptions. Metformin is an established, low-cost drug for blood sugar management, generally considered safe but with potential digestive side effects.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Yes, new research indicates that metformin, a common diabetes medication, may slow down age-related vision loss by reducing the likelihood of developing intermediate age-related macular degeneration (AMD).
A study found that diabetic patients over 55 taking metformin were 37% less likely to develop intermediate AMD over five years compared to those not taking it.
Currently, most people suffering from AMD have limited treatment options, making the potential of metformin as a new treatment a significant breakthrough.

Read more news on

Healthside-arrow
trending

Salesforce lays off 1000

trending

India US trade tariffs slashed

trending

Margot Robbie's Wuthering Heights panned

trending

CBSE board exams: key details

trending

Jana Nayagan movie court case

trending

Dhakshineswar Suresh Davis Cup hero

trending

Deepika Padukone wears Gaurav Gupta

trending

NZ vs UAE match prediction

trending

iPhone 17 Croma Valentine's sale

You may also like

Elderly Face Vision Loss as Key Treatment Excluded

4 Feb • 10 reads

article image

New Blood Test Unlocks Brain Cancer Secrets

31 Jan • 70 reads

article image

Sleepless Brain Cleans Itself While Awake

21 Jan • 27 reads

Play Tetris, Beat Multiple Sclerosis Challenges

9 Jan • 137 reads

Neuralink Breakthrough: British Man Thinks, Computer Obeys

2 Jan • 205 reads

article image